Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA question-based-review adherence

Executive Summary

More than 90 percent of ANDA submissions include quality overall summaries as of July, FDA reports. The agency requested in January that generic drug applications include a quality overall summary that answers questions related to the ANDA's Chemistry, Manufacturing and Controls section. Over the span of seven months, that number has increased dramatically, showing a positive response to the agency's use of question-based reviews. Although the goals, implemented in 2005 as a pilot program, caused some generic firms to express concern that QbR would extend review periods and provide FDA more opportunity to find fault with applications, initial experiences with the program have not shown such adverse effects (1"The Pink Sheet" Nov. 13, 2006, p. 17)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS048681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel